Download PDF
Thromb Haemost 2005; 93(02): 396-397
DOI: 10.1055/s-0037-1616248
Letters to the Editor
Schattauer GmbH

Retrospective analyses of acenocoumarol doses and bleeding complications in patients with wild type or variant cytochrome P450 CYP2C9 alleles

Laszlo Mark
1   Department of Internal Medicine II – Cardiology, Gyula, Hungary
,
Janos Marki-Zay
2   Central Laboratory, Pándy Kálmán Békés County Hospital, Gyula, Hungary
,
György Paragh
3   First Department of Medicine, Medical and Health Science Center, University of Debrecen, Debrecen, Hungary
,
Andras Katona
1   Department of Internal Medicine II – Cardiology, Gyula, Hungary
› Author Affiliations
Further Information

Publication History

Received 20 August 2004

Accepted after revision 29 November 2004

Publication Date:
14 December 2017 (online)

    Permissions and Reprints

 

 

  • References

  • 1 Visser LE, van Schaik RH, van Vliet M. et al The risk of bleeding complications in patients with cytochrome P450 CYP2C9*2 or CYP2C9*3 alleles on acenocoumarol or phenprocoumon.. Thromb Haemost 2004; 92: 61-6.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 2 Schalekamp T, van Geest-Daalderop JHH, de Vries-Goldschmeding H. et al Acenocoumarol stabilization is delayed in CYP2C9*3 carriers.. Clin Pharmacol Ther 2004; 75: 394-402.
    CrossrefPubMedGoogle Scholar
  • 3 Morin S, Bodin L, Loriot M-A. et al Pharmacogenetics of acenocoumarol pharmacodynamics.. Clin Pharmacol Ther 2004; 75: 403-14.
    CrossrefPubMedGoogle Scholar
  • 4 Takahashi H, Wilkinson GR, Padrini R. et al CYP2C9 and oral anticoagulation therapy with acenocoumarol and warfarin: similarities yet differences.. Clin Pharmacol Ther 2004; 75: 376-80.
    CrossrefPubMedGoogle Scholar